Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators.

Standard

Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. / Bamberger, A M; Milde-Langosch, K; Rössing, E; Goemann, Christoph; Löning, Thomas.

In: J CANCER RES CLIN, Vol. 127, No. 9, 9, 2001, p. 545-550.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Bamberger, AM, Milde-Langosch, K, Rössing, E, Goemann, C & Löning, T 2001, 'Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators.', J CANCER RES CLIN, vol. 127, no. 9, 9, pp. 545-550. <http://www.ncbi.nlm.nih.gov/pubmed/11570575?dopt=Citation>

APA

Vancouver

Bamberger AM, Milde-Langosch K, Rössing E, Goemann C, Löning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J CANCER RES CLIN. 2001;127(9):545-550. 9.

Bibtex

@article{bb999b172165403c800fff9b3abc53fa,
title = "Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators.",
abstract = "PURPOSE: To study the expression pattern and the role of the AP-1 (activating protein-1) family of transcription factors in endometrial carcinogenesis. METHODS: We performed Western blot experiments with specific antibodies for each of the AP-1 proteins (c-jun, junB, junD, c-fos, fosB, fra-1, fra-2) with 41 endometrial carcinomas. Expression levels of the AP-1 factors were correlated with clinico-pathologic tumor parameters, steroid receptor status, Ki-67 expression and the expression levels of eight cell cycle regulatory proteins (cyclin D1, cyclin E, cyclin B1, cdk2, cdk4, p16, p21, and Rb). RESULTS: Of the seven AP-1 factors, three (c-fos, fra2, and junB) clearly showed higher expression levels in tumors when compared to matched normal endometrial samples. These factors also correlated significantly with cell cycle promoters (c-fos with cyclin E, cyclin B1, cdk2, and cdk4; fra-2 with cyclin B1; and junB with cyclin D1). Furthermore, high c-fos expression correlated with low ER and PR immunoreactivity and high grading (G3). On the other hand, correlations with classic cell cycle inhibitors (Rb, p16, p21) have also been observed for all AP-1 factors except c-jun and junD. CONCLUSIONS: Our results indicate that the AP-1 family of transcription factors is probably implicated in the regulation of cell cycle progression and control in endometrial carcinomas. In particular, c-fos might be an additional negative prognostic factor and/or implicated in tumor progression in endometrial cancer.",
author = "Bamberger, {A M} and K Milde-Langosch and E R{\"o}ssing and Christoph Goemann and Thomas L{\"o}ning",
year = "2001",
language = "Deutsch",
volume = "127",
pages = "545--550",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators.

AU - Bamberger, A M

AU - Milde-Langosch, K

AU - Rössing, E

AU - Goemann, Christoph

AU - Löning, Thomas

PY - 2001

Y1 - 2001

N2 - PURPOSE: To study the expression pattern and the role of the AP-1 (activating protein-1) family of transcription factors in endometrial carcinogenesis. METHODS: We performed Western blot experiments with specific antibodies for each of the AP-1 proteins (c-jun, junB, junD, c-fos, fosB, fra-1, fra-2) with 41 endometrial carcinomas. Expression levels of the AP-1 factors were correlated with clinico-pathologic tumor parameters, steroid receptor status, Ki-67 expression and the expression levels of eight cell cycle regulatory proteins (cyclin D1, cyclin E, cyclin B1, cdk2, cdk4, p16, p21, and Rb). RESULTS: Of the seven AP-1 factors, three (c-fos, fra2, and junB) clearly showed higher expression levels in tumors when compared to matched normal endometrial samples. These factors also correlated significantly with cell cycle promoters (c-fos with cyclin E, cyclin B1, cdk2, and cdk4; fra-2 with cyclin B1; and junB with cyclin D1). Furthermore, high c-fos expression correlated with low ER and PR immunoreactivity and high grading (G3). On the other hand, correlations with classic cell cycle inhibitors (Rb, p16, p21) have also been observed for all AP-1 factors except c-jun and junD. CONCLUSIONS: Our results indicate that the AP-1 family of transcription factors is probably implicated in the regulation of cell cycle progression and control in endometrial carcinomas. In particular, c-fos might be an additional negative prognostic factor and/or implicated in tumor progression in endometrial cancer.

AB - PURPOSE: To study the expression pattern and the role of the AP-1 (activating protein-1) family of transcription factors in endometrial carcinogenesis. METHODS: We performed Western blot experiments with specific antibodies for each of the AP-1 proteins (c-jun, junB, junD, c-fos, fosB, fra-1, fra-2) with 41 endometrial carcinomas. Expression levels of the AP-1 factors were correlated with clinico-pathologic tumor parameters, steroid receptor status, Ki-67 expression and the expression levels of eight cell cycle regulatory proteins (cyclin D1, cyclin E, cyclin B1, cdk2, cdk4, p16, p21, and Rb). RESULTS: Of the seven AP-1 factors, three (c-fos, fra2, and junB) clearly showed higher expression levels in tumors when compared to matched normal endometrial samples. These factors also correlated significantly with cell cycle promoters (c-fos with cyclin E, cyclin B1, cdk2, and cdk4; fra-2 with cyclin B1; and junB with cyclin D1). Furthermore, high c-fos expression correlated with low ER and PR immunoreactivity and high grading (G3). On the other hand, correlations with classic cell cycle inhibitors (Rb, p16, p21) have also been observed for all AP-1 factors except c-jun and junD. CONCLUSIONS: Our results indicate that the AP-1 family of transcription factors is probably implicated in the regulation of cell cycle progression and control in endometrial carcinomas. In particular, c-fos might be an additional negative prognostic factor and/or implicated in tumor progression in endometrial cancer.

M3 - SCORING: Zeitschriftenaufsatz

VL - 127

SP - 545

EP - 550

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 9

M1 - 9

ER -